Dextrophropoxyphene effects on QTc-interval prolongation: Frequency and characteristics in relation to plasma levels
- Autores
- Keller, Guillermo Alberto; Villa Etchegoyen, Cecilia; Fernandez, Nicolas; Olivera, Nancy Monica; Quiroga, Patricia Noemí; Diez, Roberto Alejandro; Di Girolamo, Guillermo
- Año de publicación
- 2018
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Objective: To evaluate frequency and risk factors for dextropropoxypheneinduced QT-interval prolongation in the clinical setting. Design: Prospective, noninterventional, observational, longitudinal cohort approach. Electrocardiograms were blindly evaluated by independent professionals. Setting: General ward of a public hospital of metropolitan Buenos Aires. Patients, Participants: Ninety-two patients with indication of receiving dextropropoxyphene for analgesic purposes were included consecutively. All patients finished the study. Interventions: All patients were monitored with electrocardiographic controls (previous to drug administration and during steady state) to diagnose and quantify changes in the duration of the QTc interval. Main Outcome Measure: Frequency of drug-induced QTc interval prolongation, QTc interval correlation with plasma drug, and metabolite levels. Results: Ninety-two patients were studied (50 percent males). All patients received a (mean ± SD [range]) dextropropoxyphene dose of 125 ± 25[100-150] mg/d. Dextropropoxyphene and norpropoxyphene concentrations were 112 ± 38[45-199] and 65 ± 33[13-129] ng/mL, respectively. The intra-treatment QTc interval was >450 ms in only one patient (only with the Hodge correction). There were no cases of QTc > 500 ms, and there were no significant differences in the results considering different correction formulas (Bazzet, Fridericia, Framingham, Hodges). Dextropropoxyphene concentrations correlated with QTc (R > 0.45) interval and ΔQTc (R 0.52-0.87), whereas norpropoxyphene correlation was even greater for QTc (R > 0.40-0.64) and ΔQTc (R > 0.47-0.92). Depending on the QTc correction formula, eight patients presented ΔQTc > 30 ms and one patient with ΔQTc > 60 ms. No patient presented arrhythmia during the study. Conclusions: The authors did not observe a relationship between dextropropoxyphene and QTc interval prolongation at the therapeutic doses used in Argentina.
Fil: Keller, Guillermo Alberto. Gobierno de la Ciudad de Buenos Aires. Hospital de Agudos "D. F. Santojanni"; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Farmacología; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Villa Etchegoyen, Cecilia. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Laboratorio de Toxicología y Química Legal; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Fernandez, Nicolas. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Laboratorio de Toxicología y Química Legal; Argentina
Fil: Olivera, Nancy Monica. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Laboratorio de Toxicología y Química Legal; Argentina
Fil: Quiroga, Patricia Noemí. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Laboratorio de Toxicología y Química Legal; Argentina
Fil: Diez, Roberto Alejandro. Universidad de Buenos Aires. Facultad de Medicina. Departamento de Farmacología; Argentina
Fil: Di Girolamo, Guillermo. Consejo Nacional de Investigaciones Cientificas y Tecnicas. Oficina de Coordinacion Administrativa Houssay. Instituto Alberto C. Taquini de Investigaciones En Medicina Traslacional. - Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Cardiologicas "prof. Dr. Alberto C. Taquini". Instituto Alberto C. Taquini de Investigaciones En Medicina Traslacional.; Argentina - Materia
-
ADVERSE DRUG REACTION
ARRHYTHMIA
DEXTROPHROPOXYPHENE
QT-INTERVAL PROLONGATION
TORSADE DE POINTES - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/177837
Ver los metadatos del registro completo
id |
CONICETDig_8874885d67dea81c40d4c7cdce142ac3 |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/177837 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
Dextrophropoxyphene effects on QTc-interval prolongation: Frequency and characteristics in relation to plasma levelsKeller, Guillermo AlbertoVilla Etchegoyen, CeciliaFernandez, NicolasOlivera, Nancy MonicaQuiroga, Patricia NoemíDiez, Roberto AlejandroDi Girolamo, GuillermoADVERSE DRUG REACTIONARRHYTHMIADEXTROPHROPOXYPHENEQT-INTERVAL PROLONGATIONTORSADE DE POINTEShttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3Objective: To evaluate frequency and risk factors for dextropropoxypheneinduced QT-interval prolongation in the clinical setting. Design: Prospective, noninterventional, observational, longitudinal cohort approach. Electrocardiograms were blindly evaluated by independent professionals. Setting: General ward of a public hospital of metropolitan Buenos Aires. Patients, Participants: Ninety-two patients with indication of receiving dextropropoxyphene for analgesic purposes were included consecutively. All patients finished the study. Interventions: All patients were monitored with electrocardiographic controls (previous to drug administration and during steady state) to diagnose and quantify changes in the duration of the QTc interval. Main Outcome Measure: Frequency of drug-induced QTc interval prolongation, QTc interval correlation with plasma drug, and metabolite levels. Results: Ninety-two patients were studied (50 percent males). All patients received a (mean ± SD [range]) dextropropoxyphene dose of 125 ± 25[100-150] mg/d. Dextropropoxyphene and norpropoxyphene concentrations were 112 ± 38[45-199] and 65 ± 33[13-129] ng/mL, respectively. The intra-treatment QTc interval was >450 ms in only one patient (only with the Hodge correction). There were no cases of QTc > 500 ms, and there were no significant differences in the results considering different correction formulas (Bazzet, Fridericia, Framingham, Hodges). Dextropropoxyphene concentrations correlated with QTc (R > 0.45) interval and ΔQTc (R 0.52-0.87), whereas norpropoxyphene correlation was even greater for QTc (R > 0.40-0.64) and ΔQTc (R > 0.47-0.92). Depending on the QTc correction formula, eight patients presented ΔQTc > 30 ms and one patient with ΔQTc > 60 ms. No patient presented arrhythmia during the study. Conclusions: The authors did not observe a relationship between dextropropoxyphene and QTc interval prolongation at the therapeutic doses used in Argentina.Fil: Keller, Guillermo Alberto. Gobierno de la Ciudad de Buenos Aires. Hospital de Agudos "D. F. Santojanni"; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Farmacología; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Villa Etchegoyen, Cecilia. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Laboratorio de Toxicología y Química Legal; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Fernandez, Nicolas. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Laboratorio de Toxicología y Química Legal; ArgentinaFil: Olivera, Nancy Monica. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Laboratorio de Toxicología y Química Legal; ArgentinaFil: Quiroga, Patricia Noemí. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Laboratorio de Toxicología y Química Legal; ArgentinaFil: Diez, Roberto Alejandro. Universidad de Buenos Aires. Facultad de Medicina. Departamento de Farmacología; ArgentinaFil: Di Girolamo, Guillermo. Consejo Nacional de Investigaciones Cientificas y Tecnicas. Oficina de Coordinacion Administrativa Houssay. Instituto Alberto C. Taquini de Investigaciones En Medicina Traslacional. - Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Cardiologicas "prof. Dr. Alberto C. Taquini". Instituto Alberto C. Taquini de Investigaciones En Medicina Traslacional.; ArgentinaWeston Medical Publishing2018-09info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/177837Keller, Guillermo Alberto; Villa Etchegoyen, Cecilia; Fernandez, Nicolas; Olivera, Nancy Monica; Quiroga, Patricia Noemí; et al.; Dextrophropoxyphene effects on QTc-interval prolongation: Frequency and characteristics in relation to plasma levels; Weston Medical Publishing; Journal of Opioid Management; 14; 5; 9-2018; 335-3441551-74892375-0146CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.wmpllc.org/ojs/index.php/jom/article/view/2013info:eu-repo/semantics/altIdentifier/doi/10.5055/jom.2018.0466info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T09:44:06Zoai:ri.conicet.gov.ar:11336/177837instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 09:44:06.939CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
Dextrophropoxyphene effects on QTc-interval prolongation: Frequency and characteristics in relation to plasma levels |
title |
Dextrophropoxyphene effects on QTc-interval prolongation: Frequency and characteristics in relation to plasma levels |
spellingShingle |
Dextrophropoxyphene effects on QTc-interval prolongation: Frequency and characteristics in relation to plasma levels Keller, Guillermo Alberto ADVERSE DRUG REACTION ARRHYTHMIA DEXTROPHROPOXYPHENE QT-INTERVAL PROLONGATION TORSADE DE POINTES |
title_short |
Dextrophropoxyphene effects on QTc-interval prolongation: Frequency and characteristics in relation to plasma levels |
title_full |
Dextrophropoxyphene effects on QTc-interval prolongation: Frequency and characteristics in relation to plasma levels |
title_fullStr |
Dextrophropoxyphene effects on QTc-interval prolongation: Frequency and characteristics in relation to plasma levels |
title_full_unstemmed |
Dextrophropoxyphene effects on QTc-interval prolongation: Frequency and characteristics in relation to plasma levels |
title_sort |
Dextrophropoxyphene effects on QTc-interval prolongation: Frequency and characteristics in relation to plasma levels |
dc.creator.none.fl_str_mv |
Keller, Guillermo Alberto Villa Etchegoyen, Cecilia Fernandez, Nicolas Olivera, Nancy Monica Quiroga, Patricia Noemí Diez, Roberto Alejandro Di Girolamo, Guillermo |
author |
Keller, Guillermo Alberto |
author_facet |
Keller, Guillermo Alberto Villa Etchegoyen, Cecilia Fernandez, Nicolas Olivera, Nancy Monica Quiroga, Patricia Noemí Diez, Roberto Alejandro Di Girolamo, Guillermo |
author_role |
author |
author2 |
Villa Etchegoyen, Cecilia Fernandez, Nicolas Olivera, Nancy Monica Quiroga, Patricia Noemí Diez, Roberto Alejandro Di Girolamo, Guillermo |
author2_role |
author author author author author author |
dc.subject.none.fl_str_mv |
ADVERSE DRUG REACTION ARRHYTHMIA DEXTROPHROPOXYPHENE QT-INTERVAL PROLONGATION TORSADE DE POINTES |
topic |
ADVERSE DRUG REACTION ARRHYTHMIA DEXTROPHROPOXYPHENE QT-INTERVAL PROLONGATION TORSADE DE POINTES |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/3.1 https://purl.org/becyt/ford/3 |
dc.description.none.fl_txt_mv |
Objective: To evaluate frequency and risk factors for dextropropoxypheneinduced QT-interval prolongation in the clinical setting. Design: Prospective, noninterventional, observational, longitudinal cohort approach. Electrocardiograms were blindly evaluated by independent professionals. Setting: General ward of a public hospital of metropolitan Buenos Aires. Patients, Participants: Ninety-two patients with indication of receiving dextropropoxyphene for analgesic purposes were included consecutively. All patients finished the study. Interventions: All patients were monitored with electrocardiographic controls (previous to drug administration and during steady state) to diagnose and quantify changes in the duration of the QTc interval. Main Outcome Measure: Frequency of drug-induced QTc interval prolongation, QTc interval correlation with plasma drug, and metabolite levels. Results: Ninety-two patients were studied (50 percent males). All patients received a (mean ± SD [range]) dextropropoxyphene dose of 125 ± 25[100-150] mg/d. Dextropropoxyphene and norpropoxyphene concentrations were 112 ± 38[45-199] and 65 ± 33[13-129] ng/mL, respectively. The intra-treatment QTc interval was >450 ms in only one patient (only with the Hodge correction). There were no cases of QTc > 500 ms, and there were no significant differences in the results considering different correction formulas (Bazzet, Fridericia, Framingham, Hodges). Dextropropoxyphene concentrations correlated with QTc (R > 0.45) interval and ΔQTc (R 0.52-0.87), whereas norpropoxyphene correlation was even greater for QTc (R > 0.40-0.64) and ΔQTc (R > 0.47-0.92). Depending on the QTc correction formula, eight patients presented ΔQTc > 30 ms and one patient with ΔQTc > 60 ms. No patient presented arrhythmia during the study. Conclusions: The authors did not observe a relationship between dextropropoxyphene and QTc interval prolongation at the therapeutic doses used in Argentina. Fil: Keller, Guillermo Alberto. Gobierno de la Ciudad de Buenos Aires. Hospital de Agudos "D. F. Santojanni"; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Farmacología; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Villa Etchegoyen, Cecilia. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Laboratorio de Toxicología y Química Legal; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Fernandez, Nicolas. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Laboratorio de Toxicología y Química Legal; Argentina Fil: Olivera, Nancy Monica. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Laboratorio de Toxicología y Química Legal; Argentina Fil: Quiroga, Patricia Noemí. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Laboratorio de Toxicología y Química Legal; Argentina Fil: Diez, Roberto Alejandro. Universidad de Buenos Aires. Facultad de Medicina. Departamento de Farmacología; Argentina Fil: Di Girolamo, Guillermo. Consejo Nacional de Investigaciones Cientificas y Tecnicas. Oficina de Coordinacion Administrativa Houssay. Instituto Alberto C. Taquini de Investigaciones En Medicina Traslacional. - Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Cardiologicas "prof. Dr. Alberto C. Taquini". Instituto Alberto C. Taquini de Investigaciones En Medicina Traslacional.; Argentina |
description |
Objective: To evaluate frequency and risk factors for dextropropoxypheneinduced QT-interval prolongation in the clinical setting. Design: Prospective, noninterventional, observational, longitudinal cohort approach. Electrocardiograms were blindly evaluated by independent professionals. Setting: General ward of a public hospital of metropolitan Buenos Aires. Patients, Participants: Ninety-two patients with indication of receiving dextropropoxyphene for analgesic purposes were included consecutively. All patients finished the study. Interventions: All patients were monitored with electrocardiographic controls (previous to drug administration and during steady state) to diagnose and quantify changes in the duration of the QTc interval. Main Outcome Measure: Frequency of drug-induced QTc interval prolongation, QTc interval correlation with plasma drug, and metabolite levels. Results: Ninety-two patients were studied (50 percent males). All patients received a (mean ± SD [range]) dextropropoxyphene dose of 125 ± 25[100-150] mg/d. Dextropropoxyphene and norpropoxyphene concentrations were 112 ± 38[45-199] and 65 ± 33[13-129] ng/mL, respectively. The intra-treatment QTc interval was >450 ms in only one patient (only with the Hodge correction). There were no cases of QTc > 500 ms, and there were no significant differences in the results considering different correction formulas (Bazzet, Fridericia, Framingham, Hodges). Dextropropoxyphene concentrations correlated with QTc (R > 0.45) interval and ΔQTc (R 0.52-0.87), whereas norpropoxyphene correlation was even greater for QTc (R > 0.40-0.64) and ΔQTc (R > 0.47-0.92). Depending on the QTc correction formula, eight patients presented ΔQTc > 30 ms and one patient with ΔQTc > 60 ms. No patient presented arrhythmia during the study. Conclusions: The authors did not observe a relationship between dextropropoxyphene and QTc interval prolongation at the therapeutic doses used in Argentina. |
publishDate |
2018 |
dc.date.none.fl_str_mv |
2018-09 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/177837 Keller, Guillermo Alberto; Villa Etchegoyen, Cecilia; Fernandez, Nicolas; Olivera, Nancy Monica; Quiroga, Patricia Noemí; et al.; Dextrophropoxyphene effects on QTc-interval prolongation: Frequency and characteristics in relation to plasma levels; Weston Medical Publishing; Journal of Opioid Management; 14; 5; 9-2018; 335-344 1551-7489 2375-0146 CONICET Digital CONICET |
url |
http://hdl.handle.net/11336/177837 |
identifier_str_mv |
Keller, Guillermo Alberto; Villa Etchegoyen, Cecilia; Fernandez, Nicolas; Olivera, Nancy Monica; Quiroga, Patricia Noemí; et al.; Dextrophropoxyphene effects on QTc-interval prolongation: Frequency and characteristics in relation to plasma levels; Weston Medical Publishing; Journal of Opioid Management; 14; 5; 9-2018; 335-344 1551-7489 2375-0146 CONICET Digital CONICET |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/url/https://www.wmpllc.org/ojs/index.php/jom/article/view/2013 info:eu-repo/semantics/altIdentifier/doi/10.5055/jom.2018.0466 |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
Weston Medical Publishing |
publisher.none.fl_str_mv |
Weston Medical Publishing |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1844613388071600128 |
score |
13.070432 |